etavopivat

Novo Nordisk files etavopivat for sickle cell with FDA and EMA

Image
Novo Nordisk files etavopivat for sickle cell with FDA and EMA

PLAINSBORO — November 13, 2026 -- Novo Nordisk has submitted etavopivat, a once-daily oral treatment for sickle cell disease (SCD), to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Both regulators are expected to act in 2027. The filings, a New Drug Application and a Marketing Authorization Application, rest on the Phase 3 HIBISCUS trial, which in April 2026 showed a 27% reduction in vaso-occlusive crises (VOCs) and a delay of about four months to the first VOC versus placebo.